HepDirect Technology definition

HepDirect Technology means (a) any and all [***] of [***] that are activated by any [***] and/or (b) any method of making or using any of the foregoing.
HepDirect Technology means the HepDirect Know-How and the HepDirect Patents.
HepDirect Technology means all proprietary information, and all patentable and non-patentable inventions, discoveries, experience, disclosure claims, formulas, processes, procedures, compositions of matter, specifications, methods, techniques, trade secrets, technologies, data, know-how, results (including physical, chemical, biological, toxicological, pharmacological, pre-clinical and clinical data, product forms and formulations of the Licensed Compound) which are owned, possessed, developed, conceived, acquired by, or licensed to Metabasis that are useful for making prodrugs that are metabolized to an active compound primarily in the liver, and generally set forth in the specifications or supporting any of the claims in any of the WO/99/45016 publication dated 10 September 1999, the WO/00/52015 publication dated 8 September 2000, or the WO/01/18013 dated 15 March 2001 regardless of whether any such claims eventually issue in a patent in the United States or elsewhere. ICN has the meaning set forth in the preamble. INDEMNIFIED PARTY has the meaning set forth in Section 10.3.

Examples of HepDirect Technology in a sentence

  • For this purpose Ligand hereby confirms that it has no objection to Chiva’s plan to develop HepC Compounds and HepC Products using HepDirect Technology that [* * *].

  • Notwithstanding the immediately preceding sentence, Metabasis shall be free to publish scientific articles concerning the HepDirect Technology generally and concerning a compound which may become a Substituted Compound but only prior to its becoming a Substituted Compound, provided, however, that ICN is given thirty (30) days advanced written notice by Metabasis of any such proposed publication concerning the HepDirect Technology generally or concerning a compound which may become a Substituted Compound.

  • Nothing in this Section will limit Metabasis' use (itself or with any Affiliate or Third Party) of Metabasis Technology without Merck for any purpose other than for the research and development of HCV antiviral compounds [***] incorporating HepDirect Technology in the Field and subject to the license granted to Merck with respect to the Collaboration Compounds and Products under Article 3.

  • For a period of five (5) years after the Closing Date, ICN will have the right to enter into an additional collaborative arrangement with Metabasis to apply the HepDirect Technology to the extent Metabasis has the right to grant licenses or sublicenses hereunder to compounds which ICN has the right to commercialize for the discovery of new pharmaceutical products for the treatment of Hepatitis B.

  • As between Metabasis and ICN, Metabasis shall own all rights in and to any and all inventions made by or on behalf of Metabasis or ICN during the Term of this Agreement with respect to HepDirect Technology including, without limitation, any and all patents, patent claims or patent applications claiming any of the foregoing, but excluding all items set forth in Section 8.4 (b)(i) below.

  • Any settlement or other action by a Party which requires payment or other action by the other Party, or subjects the other party to liability or otherwise materially adversely affects the other Party (including in the case of Metabasis a material adverse effect on the HepDirect Technology) will require the other Party’s prior written consent, which will not be unreasonably withheld or delayed.

  • During the Term, subject to the terms and conditions of this Agreement, Ligand hereby grants to Chiva and its Affiliates an exclusive, royalty-bearing right and license under the Pradefovir Technology to make, have made, use, sell, have sold, import and export Pradefovir in the HepB Field in China and under the HepDirect Technology to make, have made, use, sell, have sold, import and export other HepB Compounds and HepB Products in the HepB Field in China.

  • Any settlement or other action by a Party which requires payment or other action by the other Party, subjects the other Party to liability or otherwise materially adversely affects the other Party (including in the case of Metabasis a material adverse effect on the HepDirect Technology) will require the other Party’s prior written consent, which will not be unreasonably withheld or delayed.

  • During the Term, subject to the terms and conditions of this Agreement, including Section 3.1, Ligand hereby grants to Chiva and its Affiliates a non-exclusive, royalty-bearing right and license under the HepDirect Technology to Develop, make, have made, use, sell, have sold, import and export HepB Compounds and HepB Products in the HepB Field and HCC Compounds and HCC Products in the HCC Field, each in the Territory.

  • During the Term, subject to the terms and conditions of this Agreement, Ligand hereby grants to Chiva and its Affiliates an exclusive, royalty-bearing right and license under the MB07133 Technology to make, have made, use, sell, have sold, import and export MB07133 in the HCC Field in China and under the HepDirect Technology to make, have made, use, sell, have sold, import and export other HCC Compounds and HCC Products in the HCC Field in China.


More Definitions of HepDirect Technology

HepDirect Technology means compositions and methods of making and using the same, of any and all [***], including all proprietary and technical information related thereto, and all patentable and non-patentable inventions, discoveries, experience, disclosure claims, formulas, processes, procedures, compositions of matter, specifications, methods, techniques, trade secrets, technologies, data, know-how, instructions, processes, formulae, materials and results related thereto which are Controlled by Metabasis and include those Patent Rights set forth in Schedule A.